Darapladib-impurity

CAS No. 1389264-17-8

Darapladib-impurity( —— )

Catalog No. M34565 CAS No. 1389264-17-8

Darapladib-impurity is the impurity of Darapladib. Darapladib inhibits lipoprotein-associated phospholipase A2 (Lp-PLA2).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 425 In Stock
10MG 626 In Stock
25MG 938 In Stock
50MG 1283 In Stock
100MG 1758 In Stock
200MG Get Quote In Stock
500MG 3525 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Darapladib-impurity
  • Note
    Research use only, not for human use.
  • Brief Description
    Darapladib-impurity is the impurity of Darapladib. Darapladib inhibits lipoprotein-associated phospholipase A2 (Lp-PLA2).
  • Description
    Darapladib-impurity is the impurity of Darapladib. Darapladib inhibits lipoprotein-associated phospholipase A2 (Lp-PLA2).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1389264-17-8
  • Formula Weight
    666.77
  • Molecular Formula
    C36H38F4N4O2S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)COc1nc(SCc2ccc(F)cc2)nc2CCCc12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Seglitide

    Peptide agonist for sst2 and sst5 somatostatin receptors. IC50/Kd values (nM) at cloned human somatostatin receptors are: > 1000 (sst1), 0.2 - 1.5 (sst2), 27 - 36 (sst3), > 127 (sst4), and 0.06 - 23 (sst5).

  • Amlodipine Diethyl E...

    Amlodipine besilate impurity E is a biochemical.

  • BRM/BRG1 ATP Inhibit...

    BRM/BRG1 ATP Inhibitor-1 is an allosteric dual Brahma homolog (BRM)/SWI/SNF related matrix-associated actin-dependent regulator of chromatin subfamily A member 2 (SMARCA2) and BRG1/SMARCA4 ATPase activity inhibitor (IC50s<0.005 μM).